Nausea symptoms in covid-19
Pro Research Analysisby 
Searched over 200M research papers
Prevalence of Nausea Symptoms in COVID-19
Nausea is a recognized gastrointestinal (GI) symptom in COVID-19 patients, with reported prevalence rates varying across studies. Meta-analyses and large cohort studies estimate that nausea occurs in approximately 5–10% of COVID-19 cases, often alongside other GI symptoms such as vomiting and diarrhea Andrews2020Perisetti2020Kumar2020+2 MORE. Some studies report nausea and/or vomiting as the most common GI complaint, affecting up to 31.6% of patients in certain cohorts . The prevalence of prolonged nausea after recovery from COVID-19 is lower, with about 3% of survivors experiencing persistent symptoms . Notably, the prevalence of GI symptoms, including nausea, tends to be higher in hospitalized patients and in studies conducted outside of China Marasco2021Sultan2020.
Nausea as an Early or Isolated Symptom of COVID-19
Nausea can present as an early symptom of COVID-19, sometimes even before respiratory symptoms appear Andrews2020Zhang2020. In some cases, patients may experience only GI symptoms, including nausea, without any respiratory complaints, which can lead to misdiagnosis or delayed treatment if not recognized Zoghi2021Zhang2020. This highlights the importance of considering GI symptoms, especially nausea, in the clinical assessment of suspected COVID-19 cases.
Persistence and Risk Factors for Nausea in COVID-19
While most GI symptoms tend to decrease in intensity or resolve within a month after hospital admission, nausea can persist longer in some patients Yusuf2021Marasco2021. Factors associated with persistent nausea include female sex, higher body mass index, the presence of dyspnea, and elevated C-reactive protein levels . Persistent GI symptoms, including nausea, can negatively impact the quality of life for COVID-19 survivors .
Mechanisms Behind Nausea in COVID-19
The development of nausea in COVID-19 is linked to the virus’s ability to infect the gastrointestinal tract. The SARS-CoV-2 virus uses the ACE2 receptor, which is highly expressed in the GI epithelium, to enter cells Andrews2020Zhang2020Perisetti2020. Infection of enterocytes can trigger the release of mediators that activate the vagus nerve and brainstem centers responsible for nausea and vomiting Andrews2020Zhang2020. Additionally, increased levels of angiotensin II, a consequence of viral interaction with ACE2, may further stimulate nausea through central mechanisms . Systemic inflammation and the use of certain medications during COVID-19 treatment may also contribute to GI symptoms Perisetti2020Sultan2020.
Clinical Implications and Recommendations
GI symptoms, including nausea, are now recognized as important features of COVID-19 and should not be overlooked in clinical practice Zoghi2021Zhang2020Perisetti2020+1 MORE. Early recognition of nausea as a possible presenting symptom can aid in timely diagnosis and management, especially in patients who lack classic respiratory symptoms. Persistent nausea after recovery warrants follow-up and supportive care to improve patient outcomes Yusuf2021Marasco2021.
Conclusion
Nausea is a common and sometimes early symptom of COVID-19, affecting a significant proportion of patients. It can occur alone or with other GI or respiratory symptoms, and may persist after recovery in some cases. Awareness of nausea as a COVID-19 symptom is essential for prompt diagnosis and comprehensive patient care Yusuf2021Marasco2021Zoghi2021+7 MORE.
Sources and full results
Most relevant research papers on this topic